Advanced non small cell lung cancer trang 1 tải miễn phí từ TAILIEUCHUNG

"Advanced non small cell lung cancer" trang 1 - tải miễn phí từ Tailieuchung

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

9 58 1

Outcome and predicting chemotoxicity in elderly patients with advanced non-small cell lung cancer

Outcome and predicting chemotoxicity in elderly patients with advanced non-small cell lung cancer

5 80 0

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

8 40 1

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

18 53 1

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

9 32 1

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

8 28 1

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

10 19 1

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

10 42 1

Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: A critical review

Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: A critical review

9 47 1

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

6 35 1

The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer

The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer

9 23 1

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report

6 27 1

Evaluation of membrane and soluble PD-L1 expression in advanced stage non-small cell lung cancer patients

Evaluation of membrane and soluble PD-L1 expression in advanced stage non-small cell lung cancer patients

9 7 1

Osimertinib in advanced EGFRT790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Osimertinib in advanced EGFRT790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

12 24 1

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using reallife data

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using reallife data

11 31 1

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1- rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1- rearranged advanced non-small cell lung cancer (NSCLC) in Canada

13 41 1

Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis

Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis

14 52 0

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: A subgroup analysis of a randomized phase III trial

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: A subgroup analysis of a randomized phase III trial

10 81 0

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer

8 48 1

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

6 26 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.